K-beauty Restructuring: Amorepacific & LG H&H's Strategic Asset Sales

Amorepacific has put its Anseong health supplement plant up for sale, while LG H&H has opened a preliminary auction for its beverage subsidiary, Haitai HTB. Both actions occurred in July 2026 and are framed as portfolio focus. This framing, however, is both accurate and incomplete. These two companies are clearing assets during the largest export boom Korean beauty has ever recorded. The deficit these sales address—capital and operating efficiency—is not the deficit that cost them their lead.

Amore Pacific HQ, ⓒAmore Pacific

What Exactly Are Amorepacific and LG H&H Selling?

Amorepacific is seeking a buyer for its health supplement manufacturing plant in Anseong, Gyeonggi Province. They have appointed a lead manager to oversee the bidding process. The plant's operating rate fell to 46 percent last year. In the first quarter, production totaled 31 billion won ($21 million), which is less than half of the site's quarterly capacity. Annual output was 171 billion won, down 7 percent year on year.

The facility was built in 1989 by Pacific Pharmaceutical, which was renamed Aestura in 2015. It became part of Amorepacific when the company acquired Aestura in 2021. Production will transfer to Amore Beauty Park, Amorepacific's flagship manufacturing complex in Osan. This sale follows the company listing its offices in Busan, Daegu, Daejeon, and Gwangju for sale in November.

Amorepacific has made it clear that this is not an exit from health supplements. Cho Yong-hwan, a public relations officer at the company, stated, "We are seeking to sell the Anseong plant to manage our assets more efficiently." He added that the VITALBEAUTIE health supplement business remains core, and this move aims to create synergy between the supplement and beauty businesses.

LG H&H is selling Haitai HTB, its wholly owned beverage subsidiary since 2011. Haitai HTB is Korea's third-largest beverage company, following Coca-Cola Beverage and Lotte Chilsung Beverage. Last year, Haitai HTB posted 343 billion won ($233 million) in sales, accounting for 7 percent of LG H&H's EBITDA. A preliminary auction and letter of intent are scheduled for this month.

Choi Jin-sung, a public relations official at LG H&H, framed the sale as strategic rather than financial. He remarked, "We are selling Haitai HTB to restructure our strategic portfolio rather than for capital gains or investment recovery."

Why Are Korea's Beauty Giants Restructuring During a Record Export Boom?

Korean cosmetics exports reached a record $7 billion in the first half of 2026, marking a 27.3 percent year-on-year increase. Korea now stands as the world's second-largest cosmetics exporter. However, almost none of that growth belongs to Amorepacific or LG H&H. Industry observers point to APR and Goodai Global as the companies that have taken market leadership, leaving the two incumbents sidelined during the industry's fastest expansion. The asset sales are widely interpreted as an attempt to regain competitive ground.

A 46 percent operating rate is a significant concern, and selling the plant is a defensible fix. However, it is essential to clarify what this fix accomplishes. It frees capital and simplifies the organization, but it does not address why companies holding brands like Sulwhasoo, Laneige, Hera, Aestura, and The Whoo are watching younger companies define what K-beauty means in 2026.

Will Buying an Indie Brand Solve It?

The anticipated next move—and the one industry observers speculate LG H&H may pursue with the proceeds from Haitai—is acquiring indie beauty brands. However, this move carries a high failure rate due to structural reasons.

Formulation is no longer a differentiator in Korean beauty. Essentially, every serious formula in the market is available from a select few original design manufacturers. This is precisely why Kolmar Korea and Cosmax are posting record results while brands fight for position above them. What an indie brand truly owns is a voice: a founder who can articulate in one sentence why the product exists, and customers who can echo that sentiment.

Acquisition often undermines this voice. The founder receives a title and a reporting line, while the unique narrative is absorbed into a brand book. Consequently, the asset that justified the price quietly ceases to function effectively.

K-beauty Restructuring: Amorepacific & LG H&H's Strategic Asset Sales

What Can a Korean Beauty Conglomerate Do That an Indie Brand Cannot?

Own time.

Amorepacific has conducted ginseng research for decades. The Whoo is built on a Korean court-medicine tradition. Aestura descends from a pharmaceutical company founded in 1989. No brand established three years ago can acquire this depth at any valuation.

These are narrative assets, not merely marketing assets—depth that takes thirty years to accumulate and roughly three sentences to explain, if anyone bothers to explain it. Mostly, it is deployed as luxury positioning: heritage packaging, a hanok-inspired counter, or a paragraph in a press release. Positioning tells a customer where to place a brand on a shelf, while a story tells them why to care. Korea's beauty conglomerates have spent thirty years perfecting the first while outsourcing the second.

K-beauty Restructuring: The Harder Spend

Selling the plant is the right call based on the numbers. However, the next step is to spend a fraction of the proceeds on a more challenging problem: determining whether anyone inside the company can explain, without a deck, why Sulwhasoo should exist in a market that now offers a thousand credible alternatives. If that answer takes more than three sentences, the next acquisition will not resolve the issue either.

Korea's manufacturing question is settled. The story question, however, remains wide open—and it is the one the incumbents are best equipped to win, if they choose to treat it as a question at all.

In conclusion, the current restructuring efforts by Amorepacific and LG H&H highlight a critical juncture in the K-beauty landscape. As the market evolves, the ability to narrate a compelling story will be just as crucial as operational efficiency. The future of these giants depends on their capacity to bridge the gap between innovation and authentic storytelling, ensuring they remain relevant in an increasingly competitive environment.